GH21 vs HBI-2376
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline
GH21
Developed by HUYABIO International, LLC. under a licence from Suzhou Genhouse Bio Co., Ltd.
NCT05183243 · Phase 1 · status unknown
This is an early-stage, single-group dose-finding study with no randomization, no blinding, and no comparison group, designed only to establish a safe dose. Studies of this type do not provide controlled evidence of benefit, and no results are available yet.
Next expected readout: December 2026 · NCT05163028 (registry estimate)
No aligned efficacy figure on record for this race.
HBI-2376
Developed by HUYABIO International, LLC.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05163028 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GH21 | HBI-2376 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- GH21
- —Not reported
- HBI-2376
- —Not reported
OS, median
- GH21
- —Not reported
- HBI-2376
- —Not reported
ORR
- GH21
- —Not reported
- HBI-2376
- —Not reported
Duration of response, median
- GH21
- —Not reported
- HBI-2376
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
GH21: no structured comparison results are available for Non-Small Cell Lung Cancer.
HBI-2376: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GH21's landscape · HBI-2376's landscape